115 results on '"Biglietto M"'
Search Results
2. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
Catalog
Books, media, physical & digital resources
3. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
4. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
5. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
6. The therapy of kidney cancer with biomolecular drugs
7. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study
8. Target therapy in metastatic renal cell carcinoma
9. P-66 Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population
10. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)
11. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II-III randomized trial
12. Cisplatin (CCDP), gemcitabine (GEM), folinic acid (FA) and fluorouracil (FU) in the treatment of locally advanced inoperable and/or metastatic pancreatic adenocarcinoma: A phase II study of the Southern Italian Oncology Group (GOIM).
13. Biweekly irinotecan (CPT-11) or Tomudex (TOM) followed by levo-leucovorin (LLV)-modulated 5FU i.v. bolus in advanced colorectal carcinoma (ACC). A Southern Italy Cooperative Group (SICOG) randomised study.
14. IRINOTECAN (CPT-11) PLUS MITOMYCIN C (MMC) FOR THE SECOND LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED COLORECTAL CARCINOMA (ACC). A PHASE I/II STUDY.
15. Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
16. Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
17. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
18. Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial
19. Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial
20. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: A randomised study by the Southern Italy Cooperative Oncology Group
21. Determinazione di ciclofosfamide e ifosfamide nelle urine mediante gascromatografia/spettrometria di massa tandem
22. Monitoraggio biologico dell’esposizione a cancerogeni: il ruolo innovativo della Spettrometria di Massa
23. Messa a punto di una metodologia per il monitoraggio biologico di soggetti professionalmente esposti a ciclofosfamide e ifofosfamide
24. Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study
25. LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab
26. BIOLOGICAL MONITIRING OF OCCUPATIONAL EXPOSED WORKERS TO CYCLOPHOSPHAMIDE
27. A7 - Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
28. 546P - Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
29. 548P - Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial
30. D02* - Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial
31. Dose-finding study of 5'-deoxy-5-fluorouridine in combination with fixed doses of cisplatin and levo-folinic acid for the treatment of advanced or recurrent squamous cell carcinoma of the head and neck
32. Anemia management with epoetin beta in anemic patients with cancer receiving chemotherapy: Pananemia observational study on clinical practice.
33. E04 - Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study
34. Bi-weekly administration of capecitabine + oxaliplatin (Xelox-2) in first-line treatment of advanced colorectal cancer (ACRC): A phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
35. Biweekly irinotecan (IRI) with 6s-folinic acid (FA)-modulated 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC): a phase III study
36. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck
37. Docetaxel (DTX) + cisplatin (CDDP) in locally advanced or metastatic head and neck cancer (HN). A phase II study
38. Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry
39. A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck
40. Biweekly administration of methotrexate (MTX), levofolinic acid (LFA), and 5-fluorouracil (5-FU) in advanced colorectal carcinomas
41. Phase II trial of paclitaxel (P) and cisplatin (COOP) in patients with advanced breast cancer refractory to anthracycline (A) therapy
42. Protracted infusion (PI) of 5-FU+FA in advanced colorectal cancer
43. Urinary metabolites of PGIα in patients with osteosarcoma
44. A phase II study of octreotide in metastatic advanced prostatic cancer (MAPC)
45. Sandostatin, a long acting somatostatin analogue, in the treatment of advanced metastatic prostatic cancer
46. Lonidamine Alone and in Combination with Other Chemotherapeutic Agents in the Treatment of Cancer Patients.
47. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: A phase I study of the Southern Italy Cooperative Oncology Group
48. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
49. Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer
50. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.